Other News To Note
Monday, January 23, 2012
Carolus Therapeutics Inc., of San Diego, published preclinical data showing CT-2009 prevented lung damage in multiple mouse models of acute lung injury. The molecule is designed to disrupt heteromers formed by the chemokines CCL5 (RANTES) and CXCL4, interfering with recruitment of neutrophils and tissue damage.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.